Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1 inhibitor +/- chemotherapy alone. The primary end point was progression-free survival (PFS). The secondary end points included overall survival, side effects and local control.

Trial Details

NCT ID
NCT06190782
Phase
PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • PD-1 inhibitor+/- chemotherapy combined with local therapy
  • systemic therapy alone
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • 1\. ≥18 years old; 2. ECOG 0-1; 3. Esophageal squamous cell carcinoma 4. ASTRO/ESTRO defined genuine oligometastatic disease and consistent with: i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →